Tang Carolyn C. 4

What Happened
Carolyn C. Tang, General Counsel of Arcus Biosciences (RCUS), was granted equity awards on January 23, 2026. The filing reports (A) 24,000 restricted stock units (RSUs) and (A) 96,000 additional RSUs reported as a derivative/award, all at $0.00 per share (i.e., awarded, not purchased). The grants are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-23; Form 4 filed 2026-01-26 (timely filing).
• Awards: 24,000 RSUs (primary grant) and 96,000 derivative/unvested RSUs; price reported $0.00 per share; cash value at grant not shown on Form 4.
• Vesting (per footnotes): the 24,000 RSUs vest in four equal annual installments beginning December 15, 2026, subject to continued service (F1). The 96,000 figure includes unvested portions of RSU grants (F2).
• Footnote F3 references an option schedule that becomes exercisable in 48 equal monthly installments after January 1, 2026; no option exercise was reported in this filing.
• Shares owned after the transaction are not specified in the excerpt provided.

Context

• These are standard equity compensation awards for an executive and do not involve a cash purchase or sale. RSUs are generally subject to time-based vesting and therefore reflect compensation/retention, not an immediate bullish or bearish trading signal.
• "Derivative" in this filing simply means unvested RSUs or other equity rights rather than a market-traded derivative instrument.